Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNephrologyAetna Oxlumo precert Coverage & Prior Auth | OpenP…
    Ask Trek AI about this page
    CurrentAetnaPolicy N/A

    Oxlumo (lumasiran) Medication Precertification Request - Coverage Criteria

    Customize your policy alerts

    Sign up for all Aetna policy alerts

    Know when Aetna releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is Aetna's precertification request form and instructions for Oxlumo (lumasiran) covering initiation and continuation of therapy for patients (including required clinical and insurance information) to obtain prior authorization for the medication.

    Policy Summary
    PayerAetna
    PolicyOxlumo (lumasiran) precertification request
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionComplete and submit the two-page precertification form with documentation confirming PH1 diagnosis or, for continuation, evidence of clinical response.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2 pagesform length
    PH1target diagnosis
    Precert phoneprecert phone
    Part BMedicare note

    Coverage / Precertification Criteria

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Precertification criteria

    Covered when ALL of the following are met:

    Initial authorization - PH1 diagnosis: Patient has a diagnosis of primary hyperoxaluria type 1 (PH1) AND diagnosis is confirmed by molecular genetic test showing a mutation in the alanine:glyoxylate aminotransferase (AGXT) gene OR by liver enzyme analysis demonstrating absent or significantly reduced AGT activity.molecular genetic test OR liver enzyme analysis

    Provider should indicate confirmation method on the form.

    Initial authorization - completed form: Completed precertification form including patient, insurance, prescriber, product (dose and frequency), and place of administration information is provided.all form fields completed

    See form sections A–F and D for administration settings.

    Continuation authorization: For continuation requests, there is documented positive response to therapy (e.g., decrease or normalization in urinary and/or plasma oxalate levels or improvement in kidney function).evidence of clinical benefit

    Document response on the continuation portion of the form.

    The precertification form specifically asks whether the requested medication will be used in combination with nedosiran. This response is collected to inform the prior authorization review and should be completed by the prescriber so combination therapy can be considered during the review process.

    The form does not contain explicit language designating treatments as not medically necessary. However, approval depends on submission of required clinical information; lack of documented confirmation of diagnosis or absence of evidence of clinical benefit on continuation requests would prevent approval per the form instructions.

    Providers should ensure all required clinical fields are completed and legible, because missing documentation (for example, confirmation of PH1 diagnosis or documentation of a positive response for continuation) may adversely affect the authorization decision.

    Billing & Diagnosis Codes

    Administration CPT codes (placeholder)CPT
    Administration code(s) (CPT):Placeholder for CPT administration codes to be provided by the prescriber/dispensing provider
    Diagnosis ICD-10 codesICD-10
    Primary ICD CodePrimary diagnosis ICD code to be provided
    Secondary ICD CodeSecondary diagnosis ICD code to be provided
    Other ICD CodeOther diagnosis ICD code to be provided

    What Providers Must Do

    Prior Authorization

    Precertification required — indicate start vs continuation and product details

    Complete the Aetna Oxlumo precertification form for each request; indicate whether this is a start of treatment or a continuation and provide the start date or date of last treatment as requested on the form. Include the requested product, dose, and frequency in the Product Information section.

    • Check the appropriate box for Start of treatment or Continuation of therapy and provide the corresponding date (Start date or Date of last treatment).
    • Enter Oxlumo (lumasiran) as the product and specify the dose and frequency in Section E.
    Step Therapy

    Document combination therapy — nedosiran query

    Answer the form question asking specifically whether Oxlumo will be used in combination with nedosiran; the form requires a yes/no response.

    • Mark Yes or No in response to: "Will the requested medication be used in combination with nedosiran?"
    Documentation Required

    Required documentation — complete all fields legibly and provide clinical evidence

    Complete all fields legibly on the two‑page precertification request including patient demographics, insurance/contact information, prescriber and dispensing provider details, product (dose/frequency), and diagnosis ICD codes; include required clinical information and, for continuation requests, evidence of response to therapy.

    • Patient information (name, DOB, contact, weight/height, allergies) per Section A.
    • Prescriber information including specialty, NPI, state license, and contact per Section C.
    • Place of administration and dispensing provider details per Section D.
    • Product name, dose, and frequency in Section E.
    • Primary and additional ICD codes in Section F.
    • Complete the required clinical information in Section G for all requests; for continuation, indicate positive response to therapy (e.g., decrease/normalization of urinary/plasma oxalate or improved kidney function).
    • Signature and date required in Section H.
    Denial Risk

    Fraud warning and potential penalties — provide truthful, complete information

    Do not submit false or concealed information; knowingly filing a request with materially false or concealed information may constitute fraud and may subject the filer to criminal and civil penalties. The plan may request additional information or clarification to evaluate requests.

    • Signature required in Section H certifies the accuracy of the information provided.
    • Be prepared to supply additional documentation if the plan requests clarification.

    Background

    This two-page precertification form is used to request authorization for lumasiran (Oxlumo) for patients with primary hyperoxaluria type 1 (PH1). For initial authorization the form requires confirmation of PH1 by either a molecular genetic test demonstrating an AGXT gene mutation or by liver enzyme analysis showing absent or significantly reduced AGT activity. For continuation requests the form requires documentation of clinical benefit, such as a decrease or normalization in urinary and/or plasma oxalate levels or improvement in kidney function.

    Definitions

    Primary hyperoxaluria type 1 (PH1) — confirmation methods
    Diagnosis queriedPrimary hyperoxaluria type 1 (PH1) — form asks whether the patient has a diagnosis of PH1.
    Genetic confirmation requiredDiagnosis must be confirmed by a molecular genetic test showing a mutation in the AGXT (alanine:glyoxylate aminotransferase) gene.
    Liver enzyme confirmation alternativeDiagnosis may alternatively be confirmed by liver enzyme analysis demonstrating absent or significantly reduced AGT activity.
    Form response optionsPrecertification form provides checkboxes to indicate presence of PH1 and the method of confirmation (molecular genetic test or liver enzyme analysis).
    Policy Summary
    PayerAetna
    PolicyOxlumo (lumasiran) precertification request
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionComplete and submit the two-page precertification form with documentation confirming PH1 diagnosis or, for continuation, evidence of clinical response.
    SourceLink
    On This Page
    Coverage / Precertification CriteriaBilling & Diagnosis CodesWhat Providers Must DoBackgroundDefinitions